These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19890063)

  • 41. [Immunotherapy of neoplasms, with special reference to the destruction of neoplastic cells].
    Hashimoto Y; Nishimura T
    Nihon Rinsho; 1979; 37(7):2872-7. PubMed ID: 93653
    [No Abstract]   [Full Text] [Related]  

  • 42. Forty-three key gene expressions involved in the effect of indoleamine 2,3-dioxygenase 1 expression on cancer prognosis may be a potential indoleamine 2,3-dioxygenase 1 inhibitor biomarker.
    Li W; Guo L; Xing Z; Fang X; Liang H; Zhang S; Shi L; Kuang C; Shi L; Zheng Y; Hu Y; Yang Q
    Clin Transl Med; 2021 Feb; 11(2):e330. PubMed ID: 33634987
    [No Abstract]   [Full Text] [Related]  

  • 43. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells.
    Dorner BG; Dorner MB; Zhou X; Opitz C; Mora A; Güttler S; Hutloff A; Mages HW; Ranke K; Schaefer M; Jack RS; Henn V; Kroczek RA
    Immunity; 2009 Nov; 31(5):823-33. PubMed ID: 19913446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determinants of cancer immunotherapy success.
    Karanikas V; Germenis A
    Expert Rev Vaccines; 2010 Dec; 9(12):1363-6. PubMed ID: 21105772
    [No Abstract]   [Full Text] [Related]  

  • 45. Tumors hijack fetal enzyme, escape killer T cells.
    Schepers K; Schumacher TN
    Nat Med; 2003 Oct; 9(10):1253-4. PubMed ID: 14520367
    [No Abstract]   [Full Text] [Related]  

  • 46. Characterization and Nonenzymatic Transformation of Three Types of Alkaloids from
    Gao D; Zhou T; Da LT; Bruhn T; Guo LL; Chen YH; Xu J; Xu MJ
    Org Lett; 2019 Nov; 21(21):8577-8581. PubMed ID: 31613107
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
    Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
    J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Highly uniform self-assembled microspheres from single macromolecule self-recognition for enhanced cancer immunotherapy.
    Shen X; Zhou Z; Qi D; Li Y; Zeng Z; He X; Xia X; Zhu C; Feng X
    Chem Commun (Camb); 2020 Aug; 56(64):9190-9193. PubMed ID: 32661548
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CMV-specific TCR-transgenic T cells for immunotherapy.
    Schub A; Schuster IG; Hammerschmidt W; Moosmann A
    J Immunol; 2009 Nov; 183(10):6819-30. PubMed ID: 19864595
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Parallel Expression of Enzyme Inhibitors of CD8T Cell Activity in Tumor Microenvironments and Secretory Endometrium.
    Ibana JA; Cutay SJ; Romero M; Schust DJ
    Reprod Sci; 2016 Mar; 23(3):289-301. PubMed ID: 26335176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resurgence or emergence of CD8+ Ts.
    Vlad G; Suciu-Foca N
    Hum Immunol; 2008 Nov; 69(11):679-80. PubMed ID: 19026353
    [No Abstract]   [Full Text] [Related]  

  • 52. [Indoleamine-2,3-dioxygenase and the immune microenvironment of chronic hepatitis B patients].
    Chen YB; Li SD; Gong JP
    Zhonghua Gan Zang Bing Za Zhi; 2008 Feb; 16(2):157-8. PubMed ID: 18304443
    [No Abstract]   [Full Text] [Related]  

  • 53. Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets.
    Mortier E; Advincula R; Kim L; Chmura S; Barrera J; Reizis B; Malynn BA; Ma A
    Immunity; 2009 Nov; 31(5):811-22. PubMed ID: 19913445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Indoleamine 2,3-dioxygenase 1 modulates the immuneresponse; the new therapeutic targets of this drug].
    Yamamoto Y; Murakami Y; Hoshi M; Saito K
    Nihon Yakurigaku Zasshi; 2013 Aug; 142(2):85-8. PubMed ID: 23934528
    [No Abstract]   [Full Text] [Related]  

  • 55. New cardiovascular risk markers: the race is on, but are there any winners?
    Røsjø H; Omland T
    Scand J Clin Lab Invest; 2008; 68(8):673-7. PubMed ID: 18836944
    [No Abstract]   [Full Text] [Related]  

  • 56. Uncovering cancer: How enlisting T cells can boost the power of immunotherapy.
    Keener AB
    Nat Med; 2017 Sep; 23(9):1006-1008. PubMed ID: 28886004
    [No Abstract]   [Full Text] [Related]  

  • 57. Overcoming obstacles to the effective immunotherapy of human cancer.
    Rosenberg SA
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12643-4. PubMed ID: 18753635
    [No Abstract]   [Full Text] [Related]  

  • 58. Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer.
    Dang Y; Disis ML
    Ann N Y Acad Sci; 2009 Sep; 1174():81-7. PubMed ID: 19769740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cutting edge: memory CD8 T cell compartment grows in size with immunological experience but nevertheless can lose function.
    Huster KM; Stemberger C; Gasteiger G; Kastenmüller W; Drexler I; Busch DH
    J Immunol; 2009 Dec; 183(11):6898-902. PubMed ID: 19890045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The quest for CD8+ memory stem cells.
    Neuenhahn M; Busch DH
    Immunity; 2009 Nov; 31(5):702-4. PubMed ID: 19932070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.